<DOC>
	<DOC>NCT01818648</DOC>
	<brief_summary>We plan to examine the gastrointestinal (GI) physiologic profile of Exenatide, a glucagon-like peptide (GLP-1) analog as a possible intestino-trophic growth factor capable of inducing small bowel adaptation and regeneration in patients with short bowel syndrome (SBS), with the potential to decrease parenteral nutrition dependence.</brief_summary>
	<brief_title>Exenatide on GI Motor Function and Permeability in Short Bowel Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Short Bowel Syndrome</mesh_term>
	<mesh_term>Mannitol</mesh_term>
	<mesh_term>Lactulose</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Patients with short bowel syndrome, between the ages of 1885 who are dependent on parenteral nutrition for at least a year and are being closely followed by the Mayo Clinic Home Parenteral Nutrition Program (HPN) with at least one multisystem evaluation a year.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>